CompletedPhase 2NCT00321932
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
Studying Idiopathic pregnancy-associated osteoporosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Minnesota
- Principal Investigator
- Linda J. Burns, MDMasonic Cancer Center, University of Minnesota
- Intervention
- calcium(dietary_supplement)
- Enrollment
- 61 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2012
Study locations (2)
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00321932 on ClinicalTrials.govOther trials for Idiopathic pregnancy-associated osteoporosis
Additional recruiting or active studies for the same condition.
See all trials for Idiopathic pregnancy-associated osteoporosis →